Immune and Neural Status of Thalassemic Patients Receiving Deferiprone or Combined Deferiprone and Deferoxamine Chelation Treatment

Autor:	Antonia Taparkou, Miranda Athanassiou-Metaxa, Florendia Kanakoudi-Tsakalidou, Vassilios Perifanis, Dimitrios Zafiriou, Marina Economou, Natalie Tourkantoni, V Tzimouli
Rok vydání:	2008
Předmět:	Adult medicine.medical_specialty Iron Overload Adolescent Pyridones T-Lymphocytes Thalassemia medicine.medical_treatment Clinical Biochemistry Splenectomy Deferoxamine Iron Chelating Agents Gastroenterology chemistry.chemical_compound Immune system Internal medicine medicine Humans Immunologic Factors Deferiprone Chelation therapy Child Evoked Potentials Genetics (clinical) Autoantibodies B-Lymphocytes business.industry beta-Thalassemia Biochemistry (medical) Autoantibody Hematology medicine.disease Chelation Therapy chemistry Immune System Ferritins Immunology Toxicity Drug Therapy Combination business medicine.drug
Zdroj:	Hemoglobin. 32:35-40
ISSN:	1532-432X 0363-0269
DOI:	10.1080/03630260701680631
Popis:	Deferiprone (L1), has previously been reported to be associated with immunological abnormalities in iron loaded thalassemia patients. However, other factors may also have similar effects such as the level of iron overload, chronic immuno-stimulation due to transfusions, splenectomy and deferoxamine (DFO). During chelation therapy with DFO, several complications have been reported, which were due to pharmacological activity and high dose toxicity with regard to both acoustic and visual effects, as well as peripheral nerve disorders that were measured by nerve conduction velocities. The immune and neural status of 44 beta-thalassemic patients, aged 10-30 years (mean 19.4 +/- 4.9), receiving L1 as a monotherapy (n = 21), or in combination with DFO (n = 23), has been followed for 2 years by monitoring the level of immunoglobulins (IgG, IgM, IgA), the level of T and B lymphocytes (CD4/CD8), the auto antibodies: anti nuclear (ANA), anti-double-stranded (anti-ds DNA), anti reticulin (anti-R1), anti-extra nuclear (anti-ENA), anti histone (anti-AHA), anti liver-kidney-muscle (anti-LKM), anti-smooth muscle (anti-SMA), anti-thyroid (anti-ATA), anti-mitochondrial (anti-AMA) antibodies and the C-reactive protein. The percentage of patients with disorders of the immune and nervous system concerned very few cases. None of our patients with pathological findings in their immunological or neurophysiological examinations presented any signs or symptoms of involvement of the immune or nervous system. Further advantages have been identified for the oral use of L1 and its combination with DFO, including synergistic efficacy and lower dosing with limited toxicity.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::896427ce3300cd1899801147e57b45bc https://doi.org/10.1080/03630260701680631 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.